pain therapy market

chronic pain

An illustration of a brain

The pain therapy market » Chronic pain

What is neuropatic pain?

Pain is a negative feeling associated with damage to the body’s tissues and is crucial to survival. Sometimes damage to the tissues from trauma or some diseases, for example, viral infection, shingles and diabetes, results in neuropathic pain that does not resolve, and the pain becomes chronic. This has no survival value and, indeed, results in a real reduction in sufferers’ quality of life.

Focus on allodynia

PharmNovo initially focuses on neuropathic pain with allodynia. Allodynia is a distressing part of neuropathic pain states. It is pain on the skin from something that shouldn’t be painful. This makes simple day-to-day activities, such as getting dressed, very unpleasant, and this has a negative impact on sufferers’ quality of life.

Allodynia is common in neuropathic pain states such as shingles, diabetic neuropathy, physical injury to nerves and migraine. Existing treatments are largely ineffective, but the drug candidate PN6047 from PharmNovo, blocks allodynia in animal models, and its potential in the human condition is clear.

The drug candidate is being developed for neuropathic pain in general, but by focusing  the study on peripheral nerve pain with mechanical allodynia, a semi-quantitative way of measuring effect can be used, which increases the likelihood of demonstrating efficacy.

NEUROPATHIC PAIN POINTS

  • Neuropathic pain, also called nerve pain, occurs when a health condition affects the nerves that carry sensations to your brain.
  • Neuropathic pain is characterized by excessive sensitivity to stimuli, including allodyniaa condition in which pain is caused by a stimulus that does not usually elicit pain and hyperalgesia in which pain is exaggerated.
  • Neuropathic pain is caused by damage or disease affecting the sensory  system. About 30% of all neuropathic pain happens because of diabetes.
  • Neuropathic pain is usually chronic; the body just sends pain signals to your brain unprompted. Neuropathic pain tends to get worse over time.
  • Most of the available treatments for neuropathic pain have only moderate efficacy and produce side effects that limit their use; therefore, there is a great need for new therapeutic approaches.
An illustration of a man having arm pain with arrows pointing to the brain

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more